International best practices for negotiating "Reimbursement Contracts" with price rebates from pharmaceutical companies

Health Affairs

Volumn 32, Issue 4, 2013, Pages 771-777

  Morgan, Steven ^a   Daw, Jamie ^a   Thomson, Paige ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTRACT; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; HEALTH CARE POLICY; HEALTH INSURANCE; MOTIVATION; REIMBURSEMENT;

ADMINISTRATIVE PERSONNEL; CONTRACTS; DEVELOPED COUNTRIES; DRUG INDUSTRY; HEALTH POLICY; HUMANS; INSURANCE, HEALTH; INTERVIEWS AS TOPIC; NEGOTIATING; PRACTICE GUIDELINES AS TOPIC; REIMBURSEMENT MECHANISMS;

EID: 84877948672     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.1268     Document Type: Article

References (14)

1. Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
2. Seiter A. A practical approach to pharmaceutical policy. Washington (DC): World Bank; 2010.
3. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179-90.
4. To access the Appendix, click on the Appendix link in the box to the right of the article online.
5. Price regulations in Canada and at least twenty-four European countries are based in part on international price comparisons. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. Differences in external price referencing in Europe-a descriptive overview. Health Policy. 2012;104(1):50-60.
6. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003; 3(3):183-205.
7. Policy makers from Denmark, France, Sweden, and Switzerland declined to participate.
8. Miles MB, Huberman AM. Qualitative data analysis: an expanded sourcebook. 2nd edition. Thousand Oaks (CA): Sage Publications; 1994.
9. In Germany the roughly 150 sickness funds have incentives to compete for cost advantages through pricevolume agreements or other arrangements, because their revenuegenerating powers are controlled by statutory limits on premiums. In Canada several provincial governments have begun to negotiate reimbursement contracts to control the cost of public drug programs. It is notable, however, that private insurers in Canada do not routinely use negotiated reimbursement contracts.
10. Bovens M. Public accountability. Chapter 8 in: Ferlie E, Lynn LE, Pollitt C, editors. The Oxford handbook of public management. Oxford (UK): Oxford University Press; 2007. p. 182-208.
11. Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. South Med Rev. 2012;5(1): 38-46.
12. Fixing of patented drug prices only after negotiating with pharma cos. Hindu Business Line [serial on the Internet]. 2012 Sep 7 [cited 28 Feb 2013]: Available from: http://www.thehindubusinessline.com/industry-and-economy/article3870409.ece
13. Yang C, Li L. Drug procurement bidding. China Bus Rev. 2010;37 (1):26-9.
14. Chalkidou K, Anderson GF, Faden R. Eliminating drug price differentials across government programmes in the USA. Health Econ Policy Law. 2011;6(1):43-64.